Скачать с ютуб Eli Lilly Expands Zepbound Access! – What’s the Catch? в хорошем качестве

Eli Lilly Expands Zepbound Access! – What’s the Catch?

Eli Lilly's Strategic Expansion with Zepbound: Patient Access or Profit Play? In this episode of The Downsized, Christopher Durham dives into Eli Lilly's recent decision to expand the distribution of its GLP-1 medication, Zepbound, via a new partnership with telehealth company Roe. While marketed to enhance patient access by lowering prices, the distribution directly through LillyDirect eliminates intermediaries but keeps the medication costs high for many patients. This shift occurs at a pivotal time with proposed changes to Medicare and Medicaid coverage for anti-obesity medicines in the U.S. Despite the potentially improved accessibility, Durham questions whether the strategy is more about maintaining profit margins than indeed reducing patient costs. The episode calls for Eli Lilly to lower prices further and release additional dosage levels to support those who need these life-changing treatments the most genuinely. Viewers are encouraged to join the conversation and attend a live stream for deeper engagement. DOWNSIZED WEBSITE: https://thedownsized.org/ JOIN CLUB DOWNSIZED: https://www.youtube.com/@thedownsized... DOWNSIZED GLP-1 COMPANION PRODUCT STORE: https://thedownsized.org/downsized-store We use Mochi Health: https://joinmochi.com/. Use Laraine’s code for $40 off: QIYGO8. 00:00 Eli Lilly's Bold Move in the GLP-1 Market 00:22 Meet the Hosts: Christopher 00:58 Breaking News: Zepbound's New Distribution Strategy 01:47 The Role of Telehealth in Expanding Access 03:25 Implications of the New Medicare and Medicaid Rule 04:07 The Controversy Over Drug Pricing 05:13 Call to Action: Lowering Prices for Better Access 07:12 Final Thoughts and Viewer Engagement